The hypolipidemic action of fibrates has recently been shown to involve the activation of peroxisome proliferator activated receptors establishing a molecular mechanism for this class of drugs. Increasing clinical trial evidence supports the efficacy of fibrates in the treatment of dyslipoproteinemias, particularly in patients with hypertriglyceridemia and low high-density lipoproteins.
机构:
Univ Pittsburgh, Dept Family Med, Fac Dev Fellow, Pittsburgh, PA 15260 USAUniv Pittsburgh, Dept Family Med, Fac Dev Fellow, Pittsburgh, PA 15260 USA
Kojima, Hajime
AMERICAN JOURNAL OF MEDICINE,
2007,
120
(09):
: E13
-
E13